Altamira Therapeutics
Quarterly Financials
| Values in thousands | 2023-06-30 |
|---|---|
Revenue | $52 |
Gross Profit | -53 |
EBITDA | -412 |
EBIT | -2,705 |
Net Income | -2,710 |
Net Change In Cash | 52 |
Free Cash Flow | -3,857 |
Cash | 49 |
Basic Shares | 209 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $305 | $63 | $174 |
Gross Profit | -1,138 | -2,176 | 174 | |
EBITDA | -1,353 | -17,636 | -6,715 | -5,263 |
EBIT | -7,270 | -17,755 | -6,792 | -5,283 |
Net Income | -7,270 | -26,528 | -17,390 | -8,200 |
Net Change In Cash | 0 | 305 | 63 | 174 |
Free Cash Flow | -11,511 | -10,826 | -16,998 | -7,158 |
Cash | 617 | 15 | 984 | 11,258 |
Basic Shares | 491 | 45 | 33 | 15 |
Earnings Calls
| Quarter | EPS |
|---|---|
2022-09-30 | $0 |
2022-06-30 | $0 |
2022-03-31 | -$1.31 |
2021-09-30 | $0 |
